Ismail Kola - UCB SA Insider

UCBJY -- USA Stock  

USD 38.45  0.000001  0.00%

Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP

Dr. Ismail Kola was Executive Vice President, New Medicines Head and Chief Scientific Officer and Member of the Executive Committee of UCB S.A. since November 2009. He joined the Company in November 2009. He holds a Doctorate in Philosophy in Medicine from the University of Cape Town, South Africa. He also holds a BS from the University of South Africa UNISA and a Bachelors degree from Rhodes University. He joined the Company from Schering Plough Corporationrationration where he was Senior Vice President, Discovery Research and Early Clinical Research Experimental Medicine, ScheringPlough Research Institute, the pharmaceutical research arm of ScheringPlough Corporationrationration, and Chief Scientific Officer, Schering Plough Corporationrationration. He came to ScheringPlough from Merck, where he was Senior Vice President and Site Head, Basic Research. He also chaired Merck Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporationrationration. Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease. He was at Monash for approximately 15 years. He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, United States, and Monash University Medical School, Melbourne, Australia a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden and is a William Pitt Fellow at Pembroke College, Cambridge University, United Kingdom. He is Member of the Board of Athersys Inc., Biotie Therapies, and Astex Pharmaceuticals.
Age: 59  EVP Since 2009  Ph.D    
32 2 559 99 99  http://www.ucb.com
Kola holds a Doctorate in Philosophy in Medicine from the University of Cape Town, South Africa. He also holds a BS from the University of South Africa UNISA and a Bachelors degree from Rhodes University. He joined the Company from Schering Plough Corporationrationrationration where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, ScheringPlough Research Institute, the pharmaceutical research arm of ScheringPlough Corporationrationrationration, and Chief Scientific Officer, Schering Plough Corporationrationrationration. He came to ScheringPlough from Merck, where he was Senior Vice President and Site Head, Basic Research. He also chaired Merck Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporationrationrationration

Ismail Kola Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.73 % meaning that it generated $13.73 on every $100 dollars invested by stockholders.
The company has accumulated 1.82 B in total debt with debt to equity ratio (D/E) of 27.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.34 which is within standard range for the sector.

Similar Executives

Found 1 records

EVP Since

Richard EgosiTeva Pharmaceutical Industries
2012

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7478 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,478 people.

UCB SA Leadership Team

Pascale Richetta, President
Detlef Thielgen, CFO
Kay Davies, Director
Dirk Teuwen, VP
Anna Richo, EVP
Viviane Monges, Director
Gerhard Mayr, Chairman
Cyril Janssen, Director
Cedric Rijckevorsel, Director, CFA
JeanChristophe Tellier, Chairman
Arnoud Calesberg, Director
Mark McDade, COO
Xavier Michel, President
Dhavalkumar Patel, President
Bharat Tewarie, President, MBA
Roch Doliveux, Chairman
Norman Ornstein, Director
Jeff Wren, President
JeanPierre Kinet, Director, Ph.D
Antje Witte, VP
Alice Dautry, Director
Harriet Edelman, Director, MBA
Ulf Wiinberg, Director
Thomas McKillop, Director, Ph.D
Charl Zyl, President
France Nivelle, VP
Fabrice Enderlin, President
Pierre Gurdjian, Director
Ismail Kola, EVP, Ph.D
Emmanuel Caeymaex, President
Evelyn Bergendal, Executive
Iris LoewFriedrich, President, Ph.D
CharlesAntoine Janssen, Director
Albrecht Graeve, Director
JeanLuc Fleurial, President
Alexander Moscho, President

Stock Performance Indicators

Did you try this?

Run Content Syndication Now
   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Content Syndication
Also Currentnly Active
Purchased over 300 shares of
few hours ago
Traded for 34.4
Purchased over 500 shares of
few hours ago
Traded for 1895.0
Purchased over 40 shares of
few hours ago
Traded for 67.2
Also please take a look at World Market Map. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.